item management s discussion and analysis of financial condition and results of operations the following discussion and analysis should be read in conjunction with the financial statements and notes thereto included elsewhere in this annual report on form k 
special note certain statements set forth below constitute forward looking statements within the meaning of section a of the securities act of  as amended  and the securities exchange act of  as amended 
see business special note regarding forward looking statements 
overview urocor markets a comprehensive range of products and services directly to urologist and managed care organizations to assist in detecting  diagnosing  treating and managing prostate cancer  bladder cancer  and kidney stone and other complex urologic disorders diseases 
the company s primary focus is helping urologists improve patient care and outcomes while reducing the total cost of managing these diseases 
during the year ended december   the company derived approximately of its revenue from diagnostic products and services that urocor labs tm provides to the urology market to assist in the diagnosis  prognosis and management of prostate cancer  bladder cancer and kidney stones disease 
the company recognizes revenue when products are sold or services are rendered 
the company typically bills various third party payors for its products and services  such as private insurance  managed care plans and governmental programs eg  medicare  as well as individual patients and physicians 
for the year ended december   approximately   and of the company s diagnostic revenue was attributable to medicare  private insurance and managed care  individual patients and physicians and hospitals  respectively 
during the year ended december   the company derived approximately of its revenue from the marketing of two therapeutic products for advanced prostate cancer including a one time termination fee of  pursuant to a co promotion agreement with a manufacturer 
pursuant to a termination notice received from the manufacturer in september  this agreement terminated on december  the company intends to pursue and acquire new therapeutic products for marketing to its clients 
the company currently has worldwide marketing and distribution rights for prostaseed registered trademark  a urocor branded line of radiation implants also referred to as seeds used in brachytherapy for early stage prostate cancer 
this product received clearance for marketing from the united states food and drug administration the fda in april  and from the nuclear regulatory commission the nrc in january the company began marketing this product in the united states in january the company also has distribution rights to a therapeutic product for use in treating certain types of bladder cancer 
the manufacturer of the product received clearance from the fda in march  and the company expects to begin marketing this product in mid year at the end of the third quarter of  the company recognized special charges related to three actions 
first  the company decided to exit the urology support services uss business to focus management and other resources on the company s core business 
second  the company accelerated efforts directed at improving its accounts receivable billing  processing and collection systems and  accordingly  increased its reserve levels for significantly past due balances 
third  the company implemented cost reduction initiatives including elimination of non strategic programs and workforce reductions 
special charges related to these three actions totaled approximately million 
during the second quarter of  the company took additional actions resulting in additional special charges of approximately million 
first  the company terminated certain managed care related marketing programs and identified significantly aged segments of its accounts receivable for which the likelihood of collections was uncertain 
second  the company launched an information systems initiative to increase productivity  reduce costs and more efficiently collect billings 
third  the company settled claims with two former clients of the uss business 
results of operations the following table sets forth certain operating data expressed as a percentage of revenue for each period indicated year ended december  revenue operating expenses direct cost of services and products selling  general and administrative expenses research and development special charges total operating expenses income loss from operations other income expense income loss before income taxes income taxes net income loss year ended december  compared to year ended december  revenue 
revenue decreased  from approximately million in to approximately million in diagnostic services revenue increased for resulting from increase in case volume and a decrease in overall average unit price 
the main contributor to the decrease in overall average unit price was the higher volume growth for lower priced products  including stones and microbiology  than in most of the company s higher priced products 
the diagnostics case volume rate of increase decreased compared to prior years primarily the result of the elimination of certain managed care related marketing programs and related collection efforts that resulted in the loss of some clients and decreased product usage from other clients 
the company s client base at the end of was approximately  urologist of which used two or more products compared to  urologists at the end of of which used two or more products 
therapeutics product revenue decreased from approximately million for to approximately million for principally due to a restructuring effective january   of the compensation terms of the related co promotion agreement to which such and revenues were attributable 
therapeutic product co promotion revenue in included an early termination fee of  which became payable before march by the manufacturer pursuant to the terms of the co promotion agreement 
payment of the fee was triggered by the manufacturer s delivery of notice in september of termination  without cause  of the agreement  effective december  direct cost of services and products 
as a percentage of revenue  direct cost of products and services increased to for from for in the aggregate  direct costs of services and products decreased from approximately million in to approximately million in direct costs for included approximately  for non recurring direct costs associated with the uss business that the company exited in late as a percent of revenue  direct costs for excluding the direct cost associated with uss would have been 
the increase in this percentage for compared to the adjusted period was the result of the decline in therapeutics co promotion revenue under the restructured terms of the co promotion agreement 
selling  general and administrative expenses 
as a percentage of revenue  selling  general and administrative expenses increased to for from approximately in in the aggregate  selling  general and administrative expenses increased  from approximately million for to approximately million in selling  general and administrative expenses in included approximately  for non recurring costs associated with the uss business that the company exited in late the increase in selling  general administrative expenses was due principally to increased management personnel  and depreciation costs related to information services and billing efforts  increased convention and meeting costs and the incurrence of over million related to personnel  marketing and information systems in anticipation of the upcoming launch of the company s prostaseed product 
research and development 
as a percentage of revenue  research and development expenses decreased to for from for in the aggregate  research and development costs decreased from approximately million in to approximately million in the decrease in expenses was due primarily to elimination of non strategic projects in the third quarter resulting in overall lower base research and development program costs 
special charges 
during the second quarter of  the company recognized special charges related primarily to two items 
first  the company terminated certain managed care related marketing programs and identified significantly aged segments of its accounts receivable for which the likelihood of collectibility was doubtful 
accordingly  a provision of approximately million was made for these receivable balances 
second  the company launched an information systems initiative to increase productivity  decrease costs and more efficiently collect billings 
as a result of this new operation focus for information systems  the company restructured its information systems function and terminated certain existing systems and internal software development projects  resulting in approximately million in asset write offs and approximately  in severance and outplacement costs 
additionally  the company settled claims with two former clients of the uss business  which the company exited in late these settlements totaled approximately  in excess of amounts that had been accrued in the aggregate charges for these three items totaled approximately million for aggregate special charges for were approximately million  including million in accounts receivable provision  approximately million in exit costs related to uss and approximately million in non strategic program asset write offs  severance and other restructuring costs 
the following table sets forth the effects of the special charges and the operating losses of uss on urocor s operating income for the and year ended year ended december  december  operating loss  as reported   operating income  excluding special charges and uss operating losses   other income expense 
interest income net of interest expense decreased  from approximately million in to approximately  in this decline was due principally to decreased cash  cash equivalents and investments compared to  resulting from the use of such resources to fund stock repurchases and capital expenditures 
other expenses of approximately  the non recurring expense was primarily due to non recurring charges for professional fees related to implementing the company s stockholders rights plan and review of an unsolicited purported acquisition offer in the third quarter of the following table sets forth the effects of the special charges  the operating losses of uss in and the non recurring expenses on urocor s net income and earnings per share for and year ended year ended december  december  net loss  as reported   net income  excluding special charges  uss operating losses and non recurring expense   diluted loss per share  as reported 

diluted earnings per share  excluding special charges  uss operating losses and non recurring expense 

the most significant contributor to the decline in the adjusted operating and net income figures from to set forth in the tables above was the decrease in therapeutic revenue as further discussed in revenue above 
income taxes 
income tax benefit recorded in was approximately million resulting in an effective federal and state income tax rate 
income tax benefit recorded for was approximately million based upon an effective federal and state income tax rate 
year ended december  compared to year ended december  revenue 
revenue increased  from approximately million in to approximately million in this increase was due primarily to an increase in case volume of due primarily to expansion of the company s client base from  to  urologists in december and  respectively  and increased utilization of the company s diagnostic products and services by existing clients 
revenue also increased as a result of therapeutic product co promotion revenue  from approximately  in to approximately million for the year ended december  direct cost of services and products 
as a percentage of revenue  direct expenses decreased to for compared to in in the aggregate  direct cost of services and products increased  from approximately million in to approximately million in this increase was due principally to higher personnel costs and supply and distribution costs  resulting from increased case volume 
incremental costs also resulted from uss business operations through the third quarter of  and expanded utilization of the company s wide area network report delivery system by the company s clients 
the decrease as a percentage of revenue was due principally to growth of the company s therapeutic revenue with negligible associated direct costs  offset by growth of the company s serum product  which has a lower profit margin than those of most of the company s other products  as well as incremental uss operations costs and wide area network report delivery system costs 
selling  general and administrative expenses 
as a percentage of revenue  selling  general and administrative expenses increased to for compared to in in the aggregate selling  general and administrative expenses increased  from approximately million in to approximately million in this increase was due principally to higher personnel costs related to sales staff  management information services personnel and accounts receivable personnel and increased provision for doubtful accounts receivable 
research and development 
as a percentage of revenue  research and development expenses decreased to for compared to in in the aggregate research and development expenses decreased  from approximately million in to approximately million in this decrease was due primarily to timing of completed external research activities and elimination of non strategic projects in the third quarter of special charges and uss operations 
during the third quarter of  the company recognized special charges related to three actions 
first  the company exited the uss business to focus management and other resources on the company s core business 
the related exit costs totaled approximately million and included estimated expenses for orderly termination and transition of uss service contracts  related asset write downs and severance and outplacement costs for uss employees 
second  as part of its ongoing assessment of accounts receivable and reserve adequacy  the company determined that collection costs on specific aged segments of its accounts receivable outweighed the expected proceeds 
accordingly  a provision of million was made for these older receivable balances 
third  the company implemented cost reduction initiatives including elimination of non strategic programs and workforce reductions  resulting in approximately  in asset write downs  approximately  in severance and outplacement costs and approximately  in other non recurring costs related to these initiatives 
the aggregate charges for these three actions totaled approximately million for the year ended december   and there were no such charges for the year ended december  operating losses for the uss business  exclusive of costs to exit the business  are reflected as operating expenses in excess of associated revenue and totaled approximately million for the year 
the table appearing in special charges in the discussion above of compared to sets forth the effects of the special charges and the operating losses of uss on urocor s operating income for the year ended december  other income expense 
interest income net of interest expense decreased from approximately million in to approximately million in due principally to the decrease in cash  cash equivalents and investments resulting from capital expenditures and an increase in accounts receivable 
other expenses of approximately  was primarily due to non recurring charges for professional advisor fees related to implementing the company s stockholder rights plan and reviewing an unsolicited purported acquisition offer in the third quarter of the table above sets forth the effect of the special charges  the operating losses of uss and the other non recurring expenses on urocor s net income and diluted earnings per share for the year ended december  income taxes 
the income tax benefits recorded for increased from approximately million in to approximately million in reflecting income tax benefits at a effective rate for income tax benefits of million for reflected a one time benefit to record the future tax benefits of loss carryforwards and other deferred tax items 
quarterly results of operations the following table presents the company s results of operations for the last calendar quarters 
this data is unaudited and includes  in the opinion of the company s management  all adjustments necessary to present fairly the data in accordance with generally accepted accounting principles 
such quarterly results are not necessarily indicative of future results of operations 
the company s quarterly operating results are affected by a wide variety of factors  many of which are outside the company s control  that could materially and adversely affect revenue  operating expenses and income 
these factors include the volume and timing of cases received  seasonality related to the timing of patient visits to the urologist s office as affected by weather and insurance deductible status  competitive pricing pressures  availability and cost of diagnostic supplies  changes in the mix of products sold  the timing and results of accounts receivable collections and write offs  the timing and costs of new product and technology introductions by the company or its competitors and retention and expansion of the company s sales force 
the company s results of operations for the fourth quarter of include a million income tax benefit and a charge of  to increase the allowance for doubtful accounts 
results for the third quarter of includes special charges of million to increase the allowance for doubtful accounts  million related to uss exit costs  and million related to non strategic program asset write offs and other restructuring costs including severance costs for workforce reduction 
results for the second quarter of includes special charges of million to increase the allowance for doubtful accounts  million related to information processing initiatives and approximately  severance and outplacement costs and  related to settlements with former uss clients 
dollars in thousands unaudited q q q q q q q q revenue         operating expenses direct costs of services and products         selling  general and administrative expenses         research and development special charges  income loss from operations   other income expense income loss before income taxes    income tax benefit expense   net income loss     dollars in thousands unaudited q q q q revenue     operating expenses direct costs of services and products     selling  general and administrative expenses     research and development special charges  income loss from operations   other income expense income loss before income taxes   income tax benefit expense  net income loss  liquidity and capital resources as of december   cash  cash equivalents and marketable investments totaled approximately million and the company s working capital was approximately million 
as of december   the components of cash  cash equivalents and marketable investments were cash and cash equivalents of approximately million  short term marketable investments of million and long term marketable investments of approximately million 
such marketable investments consisted principally of high grade fixed income securities  with a maturity of less than two years 
accounts receivable  net of allowance for doubtful accounts  totaled approximately million at december   a decrease of approximately million from december   or 
this decrease was principally attributable to improved collections and the special charge for additional bad debt recorded in the second quarter if at december   the company s average number of days sales in net diagnostics receivables was approximately compared to approximately at december  virtually all of the company s diagnostic services are rendered on a fee for service basis 
accordingly  the company assumes the financial risk related to collection  including potential inability to collect accounts  long collection cycles for accounts receivable  difficulties in gathering complete and accurate billing information and delays attendant to reimbursement by third party payors  such as governmental programs  private insurance plans and managed care organizations 
the company monitors the collection quality of its accounts receivable through analytical review of aging categories by payor group and collections performance 
in the second quarter of  the company recorded a special charge of million to increase the allowance for doubtful accounts in respect of terminating certain managed care related marketing programs and identifying significantly aged segments of its accounts receivable for which the likelihood of collectibility was doubtful 
in  the company recorded a special charge of million to increase the allowance for doubtful accounts in respect of certain accounts for which the company determined that the cost of additional collection efforts would exceed the expected collections 
also in  the company determined that it had not sent invoices timely to certain patients  primarily managed care patients  for co pay  deductible and other amounts relating principally to services rendered in in december  the company commenced collection efforts for certain of these amounts 
the company has taken steps to implement systems and processing changes intended to improve its billing procedures and related collection results  including actions taken in respect to the unsent invoices 
partially in response to the collection efforts undertaken by the company for the previously delayed invoices to patients for co pays  deductibles and other amounts determined in  some urologist for such patients discontinued or reduced their use of the company s diagnostic services 
the loss of any additional clients business could adversely affect the rate of the company s growth in revenue and the company s results of operations 
while the company maintains what it believes to be an adequate allowance for doubtful accounts  there can be no assurances that the company s ongoing assessment of accounts receivable will not result in the need for additional provision for doubtful accounts 
such additional provision could have an adverse effect on the company s financial position and results of operations 
in october  the company entered into a co promotion agreement with the manufacturer of two therapeutic products 
this agreement was revised effective january   and for  the company recorded revenue of approximately million including a non recurring fee of  as a result of early termination under the agreement  as compared to approximately million revenue for in september  the manufacturer sent the company a notice of termination without cause of the agreement effective december  the company intends to pursue the acquisition of new therapeutic products for marketing to its clients 
the company currently markets two products  prostaseed and persist  and has rights to market one other product that received fda marketing clearance in march operating activities provided net cash of approximately million in compared to using net cash of approximately  for the net cash provided by operating activities in was primarily the result of the net loss of approximately million and the related deferred tax benefit of approximately million  offset by a special charge of approximately million for asset write offs related to restructuring the company s information systems function and terminating certain existing systems and internal software development projects in the second quarter  a decrease in accounts receivable of approximately million resulting from increased collections and a special charge in the second quarter  depreciation and amortization of approximately million and a decrease in other current assets of approximately  net cash used in investing activities for was approximately million and consisted primarily of maturities of short term marketable investments of approximately million  offset by capital expenditures of approximately million  purchases of long term marketable investment of approximately  and an increase in intangibles and other assets of approximately  primarily related to progress payments for marketing distribution rights 
the company s capital expenditures of approximately million in were primarily for leasehold improvements  furniture and fixtures and computer equipment and software associated with the company s relocation to newly constructed facilities adjacent to the former facilities 
of the total amount  approximately  related to internal software development costs for information services 
while future capital expenditures will depend upon a number of factors  the level of expenditures is expected to be comparable to current levels as the company expands to deliver therapeutics and information services and continues to enhance current diagnostic services and operational capabilities 
the company intends to finance the majority of these capital expenditures with existing cash and investment balances and possibly new debt 
in march  a therapeutic product for bladder cancer for which the company has distribution rights received clearance from the fda for marketing in the united states 
the total cost of the distribution rights for this product is million  of which the company has paid million 
with the fda clearance of this product for marketing  all milestones have been met 
the company is now obligated to pay the remaining million in three payments during the first payment of  is due in april  the second payment of  is due in july and the final payment of  is due in october the company intends to make these payments from existing cash and investment balances or possibly new debt 
during  the company obtained marketing and other rights to two other therapeutic products  and is obligated to pay an additional  to the manufacturers based on achievement of certain milestones 
in april  the company paid one of such manufacturers  upon receiving marketing clearance from the fda 
as of december  the company advanced that manufacturer  toward the next milestone and approximately  towards other costs 
the company also advanced another manufacturer  toward future inventory purchases during if inventory purchases are not made  the manufacturer is obligated to return the advance prior to january  as milestones are achieved  the company intends to make additional payments from existing cash and investment balances or possibly new debt 
in april  the company s board of directors authorized the repurchase of up to million of the company s common stock 
as of december  the company had repurchased approximately million or approximately million shares of its common stock 
the company intends to fund any such purchases using available cash and cash flow from operations  and may elect to supplement its cash position with new debt 
the company paid current income taxes of approximately  during at december   the company estimated net operating loss carryforwards of approximately million were available to reduce future taxable income after considering certain annual limitations 
the company believes that its existing capital resources will be sufficient to provide the funds necessary to maintain its present level of operations and implement its currently planned growth strategy 
however  there may be circumstances or new business opportunities that would require additional resources 
in such event  the company may be required to seek additional financing  and there is no assurance that the company would be able to obtain such financing on a timely basis or on acceptable terms 
item a 
quantitative and qualitative disclosures about market risk pursuant to the company s investment policy  idle and excess funds are invested in high grade  fixed income securities generally for no more than two years and are classified as available for sale 
marketable securities at december  consisted primarily of debt securities with maturities as long as two years 
the company considers any net unrealized gain or loss on these investments to be temporary  and reflects such gains or losses as a component of stockholders equity 
as of december  and  there were no material net unrealized gains or losses on these investments 

